In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA User Fee Reauthorization Passes House, Awaits Conference

This article was originally published in The Gray Sheet

Executive Summary

The House passed broad-based FDA legislation July 11 that includes a package to reauthorize the medical device user fee program

You may also be interested in...



Congress Approves FDA Reform/User Fee Bill In The Nick Of Time

Congress gave final approval last week to a massive FDA bill that renews device and drug user fees for five years and strengthens product safety programs

Congress Approves FDA Reform/User Fee Bill In The Nick Of Time

Congress gave final approval last week to a massive FDA bill that renews device and drug user fees for five years and strengthens product safety programs

Congress Down To The Wire On FDA User Fee Reauthorization, SCHIP

FDA reform legislation reauthorizing device and drug user fees may not be finalized by Congress in time to avoid agency layoffs

Related Content

UsernamePublicRestriction

Register

MT025020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel